Kario Kazuomi, Ogawa Hisao, Okumura Ken, Okura Takafumi, Saito Shigeru, Ueno Takafumi, Haskin Russel, Negoita Manuela, Shimada Kazuyuki, on behalf of, the SYMPLICITY, HTN-Japan Investigators
Circulation Journal 2015年
<b><i>Background:</i></b>SYMPLICITY HTN-Japan is a prospective, randomized, controlled trial comparing renal artery denervation (RDN) with standard pharmacotherapy for treatment of resistant hypertension (systolic blood pressure [SBP] ≥160 mmHg on ≥3 anti-hypertensive drugs including a diuretic for ≥6 weeks). When SYMPLICITY HTN-3 failed to meet the primary efficacy endpoint, the HTN-Japan enrollm